GPCR Therapeutics, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gpcr.co.kr
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05561751
- Locations
- 🇺🇸
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Florida (UF) - Shands Cancer Center, Gainesville, Florida, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
- Conditions
- Non-Hodgkin LymphomaMultiple MyelomaHodgkin Disease
- Interventions
- Drug: TG-0054 combined with G-CSF
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02104427
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
- Conditions
- Multiple MyelomaHodgkin's DiseaseNon-hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01458288
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
- Conditions
- Multiple MyelomaNon-Hodgkin LymphomaHodgkin Disease
- Interventions
- Drug: TG-0054 (2.24 mg/kg)Drug: TG-0054 (3.14 mg/kg)
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01018979
- Locations
- 🇨🇳
Chang-Gung Memorial Hospital Chiayi, Chiayi, Taiwan
🇨🇳Buddist Tzu Chi General Hospital, Hualien, Taiwan
🇨🇳Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT00822341
- Locations
- 🇺🇸
PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center, Baltimore, Maryland, United States